Long-term treatment with mammalian target of rapamycin inhibitor does not benefit patients with autosomal dominant polycystic kidney disease: A meta-analysis

Nephron - Clinical Practice

Volumn 124, Issue 1-2, 2013, Pages 10-16

  Xue, Cheng ^a   Dai, Bing ^a   Mei, Changlin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Autosomal dominant polycystic kidney disease; Meta analysis; Rapamycin

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO; RAMIPRIL; RAPAMYCIN; TELMISARTAN;

ADVERSE OUTCOME; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; COCHRANE LIBRARY; DATA BASE; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY PARENCHYMA; KIDNEY POLYCYSTIC DISEASE; LONG TERM CARE; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL SIGNIFICANCE;

EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROTEINURIA; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84890443229     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000354398     Document Type: Article

References (24)

1. Grantham JJ: Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359: 1477-1485.
2. Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287-1301.
3. Grantham JJ, Chapman AB, Torres VE: Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 2006; 1: 148-157.
4. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, et al: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006; 103: 5466-5471.
5. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, et al: Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006; 21: 598-604.
6. Tao Y, Kim J, Schrier RW, Edelstein CL: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005; 16: 46-51.
7. Qian Q, Du H, King BF, Kumar S, Dean PG, et al: Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 2008; 19: 631-638.
8. Faivre S, Kroemer G, Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5: 671- 688.
9. Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, et al: Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 830-840.
10. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, et al: Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 820-829.
11. Perico N, Antiga L, Caroli A, Ruggenenti P, Fasolini G, et al: Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 2010; 21: 1031-1040.
12. Soliman A, Zamil S, Lotfy A, Ismail E: Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment. Transplant Proc 2012; 44: 2936-2939.
13. Stallone G, Infante B, Grandaliano G, Bristogiannis C, Macarini L, et al: Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. Nephrol Dial Transplant 2012; 27: 3560-3567.
14. Higgins J, Green S: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. www.cochrane-handbook.org. 2011.
15. Grantham JJ, Cook LT, Wetzel LH, Cadnapaphornchai MA, Bae KT: Evidence of extraordinary growth in the progressive enlargement of renal cysts. Clin J Am Soc Nephrol 2010; 5: 889-896.
16. Torres VE, Boletta A, Chapman A, Gattone V, Pei Y, et al: Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol 2010; 5: 1312-1329.
17. Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, et al: PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 2007; 117: 730-738.
18. Shillingford JM, Leamon CP, Vlahov IR, Weimbs T: Folate-conjugated rapamycin slows progression of polycystic kidney disease. J Am Soc Nephrol 2012; 23: 1674-1681.
19. Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, et al: Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 2007; 30: 253-259.
20. Ozkok A, Akpinar TS, Tufan F, Kanitez NA, Uysal M, et al: Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience. Clin Exp Nephrol 2013; 17: 345-351.
21. Stephany BR, Augustine JJ, Krishnamurthi V, Goldfarb DA, Flechner SM, et al: Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitorbased immunosuppression in live donor kidney transplantation. Transplantation 2006; 82: 368-374.
22. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, et al: Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242.
23. Kasiske BL, de Mattos A, Flechner SM, Gallon L, Meier-Kriesche HU, et al: Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008; 8: 1384-1392.
24. Lambert PC, Sutton AJ, Abrams KR, Jones DR: A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol 2002; 55: 86-94.